Literature DB >> 19155975

Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.

Kristina Bartsch1, Haifa Al-Ali, Annette Reinhardt, Christina Franke, Michael Hudecek, Manja Kamprad, Sabine Tschiedel, Michael Cross, Dietger Niederwieser, Chiara Gentilini.   

Abstract

BACKGROUND: Human bone marrow contains hematopoietic stem cells and stroma cells known as mesenchymal stem cells (MSC). MSC are cells with the morphological features of fibroblasts, which, in addition to their nursing function for hematopoietic stem cells, retain the ability to differentiate into cartilage, bone, fat, muscle, and tendon and have an important immunmodulatory function. To understand in more detail hematopoietic engraftment and immune modulation after hematopoietic cell transplantation, we investigated the ability of donor MSC to engraft after hematopoietic cell transplantation in dependency to the conditioning regimen (myeloablative vs. reduced intensity) and source of the graft (bone marrow vs. peripheral blood).
METHODS: Bone marrow MSC of 12 patients were analyzed, a median of 23.4 (range 0.9-137.8) months after human leukocyte antigen matched but gender mismatched bone marrow transplantation after myeloablative conditioning (n=4) or peripheral blood cell transplantation after myeloablative (n=4) or reduced intensity conditioning (n=4). MSC were characterized by morphology, positivity for CD 105+, CD73+, CD 44+, and CD 90+, and by their capacity to differentiate into adipocytic and osteogenic cells. Recipient and donor origins were determined by fluorescent in situ hybridization for sex chromosomes.
RESULTS: While overall blood and bone marrow chimerism was 100% donor type, MSC remained in all patients of recipient origin (>96%). There was no difference between patients receiving bone marrow and peripheral blood grafts, nor was any difference observed between patients receiving full intensity in comparison with reduced intensity conditioning.
CONCLUSIONS: We conclude that MSC remain of host type irrespective of the conditioning regimen and graft source.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155975     DOI: 10.1097/TP.0b013e3181938998

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

Review 1.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 2.  Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?

Authors:  Yasuo Miura; Satoshi Yoshioka; Hisayuki Yao; Akifumi Takaori-Kondo; Taira Maekawa; Tatsuo Ichinohe
Journal:  Chimerism       Date:  2013-07-11

3.  Intramarrow injection of beta-catenin-activated, but not naive mesenchymal stromal cells stimulates self-renewal of hematopoietic stem cells in bone marrow.

Authors:  Ji Yeon Ahn; Gyeongsin Park; Jae Seung Shim; Jong Wook Lee; Il Hoan Oh
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

4.  Hematopoietic-to-mesenchymal transition of adipose tissue macrophages is regulated by integrin β1 and fabricated fibrin matrices.

Authors:  Kathleen M Gavin; Susan M Majka; Wendy M Kohrt; Heidi L Miller; Timothy M Sullivan; Dwight J Klemm
Journal:  Adipocyte       Date:  2017-04-03       Impact factor: 4.534

5.  Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality.

Authors:  Elizabeth O Stenger; Raghavan Chinnadurai; Shala Yuan; Marco Garcia; Dalia Arafat; Greg Gibson; Lakshmanan Krishnamurti; Jacques Galipeau
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-26       Impact factor: 5.742

Review 6.  Acquired Aplastic Anemia: What Have We Learned and What Is in the Horizon?

Authors:  Süreyya Savaşan
Journal:  Pediatr Clin North Am       Date:  2018-06       Impact factor: 3.278

7.  Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment.

Authors:  Ye Chen; Rodrigo Jacamo; Yue-xi Shi; Rui-yu Wang; Venkata Lokesh Battula; Sergej Konoplev; Dirk Strunk; Nicole A Hofmann; Andreas Reinisch; Marina Konopleva; Michael Andreeff
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

Review 8.  The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

9.  Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.

Authors:  Ulrike Bacher; Svetlana Asenova; Anita Badbaran; Axel Rolf Zander; Haefaa Alchalby; Boris Fehse; Nicolaus Kröger; Claudia Lange; Francis Ayuk
Journal:  Clin Exp Med       Date:  2009-07-23       Impact factor: 3.984

10.  Tumor-associated fibroblasts predominantly come from local and not circulating precursors.

Authors:  Ainhoa Arina; Christian Idel; Elizabeth M Hyjek; Maria-Luisa Alegre; Ying Wang; Vytautas P Bindokas; Ralph R Weichselbaum; Hans Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.